BusinessNetworkNewsWire Announces Publication on Good News in Biotech Advancements Through Cannabis Delivery TechnologyBy Nasdaq OMXApr 25, 2018, 12:32 PM UTC
BusinessAxsome Therapeutics Hosts R&D Day Today with Key Opinion Leaders Focusing on AXS-05 and Unmet Needs in Depression, Alzheimer’s Disease Agitation, and Nicotine DependenceBy Nasdaq OMXApr 24, 2018, 11:01 AM UTC
BusinessAxsome Therapeutics Announces First Patient Enrolled in Phase 2 Clinical Trial of AXS-05 in Smoking CessationBy Nasdaq OMXApr 23, 2018, 11:00 AM UTC
BusinessAxsome Therapeutics to Host R&D Day with Key Opinion Leaders Focused on AXS-05 and Unmet Needs in Depression, Alzheimer’s Disease Agitation, and Nicotine DependenceBy Nasdaq OMXMar 27, 2018, 11:00 AM UTC
BusinessAxsome Therapeutics Collaborates with World-Leading Nicotine Addiction Research Center for Phase 2 Trial of AXS-05 in Smoking CessationBy Nasdaq OMXDec 14, 2017, 12:00 PM UTC
BusinessSelecta Biosciences Commences Dosing in Phase 1 Clinical Trial of Nicotine Vaccine for Smoking Cessation and Relapse PreventionBy Nasdaq OMXMay 11, 2017, 8:01 PM UTC
BusinessSharecare and the American Cancer Society to Host Fourth Annual Great American Smokeout Twitter ChatBy Nasdaq OMXNov 15, 2016, 2:00 PM UTC
